SCHEMBL706414

SCHEMBL706414

CS(=O)(=O)Oc1ccc(C(=O)Nc2nccs2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.71
NPC1 O15118 7/20 0.71
HSD17B10 Q99714 2/20 0.68
SMN1; SMN2 Q16637 4/20 0.64
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
LMNA P02545 3/20 0.60
RECQL P46063 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
AGER Q15109 1/20 0.60
POLB P06746 1/20 0.60
SCD O00767 1/20 0.58
ADORA2A P29274 4/20 0.56
MAPK1 P28482 2/20 0.56
KDM4E B2RXH2 1/20 0.55
MAPT P10636 1/20 0.55
ALDH1A1 P00352 2/20 0.55
TSHR P16473 2/20 0.55
GBA1 P04062 1/20 0.55
HPGD P15428 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4755922 0.85 RAB9A (0.71) RAB9ANPC1HSD17B10SMN1; SMN2MEN1
SCHEMBL28478360 0.83 RAB9A (1.00) RAB9ANPC1HSD17B10SMN1; SMN2MEN1
SCHEMBL4756204 0.82 SMN1; SMN2 (0.52) RAB9ANPC1HSD17B10SMN1; SMN2MAPK1
SCHEMBL404981 0.81 RAB9A (0.75) RAB9ANPC1HSD17B10SMN1; SMN2MEN1
SCHEMBL4756199 0.81 RAB9A (0.62) RAB9ANPC1HSD17B10SMN1; SMN2MEN1
SCHEMBL10113829 0.81 RAB9A (0.69) RAB9ANPC1HSD17B10SMN1; SMN2MEN1
SCHEMBL4756018 0.81 RAB9A (0.62) RAB9ANPC1HSD17B10SMN1; SMN2MEN1
SCHEMBL4756271 0.81 RAB9A (0.62) RAB9ANPC1HSD17B10SMN1; SMN2MEN1
SCHEMBL2753283 0.80 RAB9A (0.92) RAB9ANPC1HSD17B10SMN1; SMN2MEN1
SCHEMBL4295195 0.79 RAB9A (0.76) RAB9ANPC1HSD17B10SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2178852-B9 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LAB LC (US) 2016-06-22 EP disclosed
EP-2178852-B1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LAB LC (US) 2015-07-22 EP disclosed
US-8895752-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES L.C. (US) 2014-11-25 US disclosed
US-8895752-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES L.C. (US) 2014-11-25 US disclosed
US-8895752-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES L.C. (US) 2014-11-25 US disclosed
US-20120122939-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES, L.C. 2012-05-17 US disclosed
US-8124632-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES, L.C. (US) 2012-02-28 US disclosed
US-8124632-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES, L.C. (US) 2012-02-28 US disclosed
US-8124632-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES, L.C. (US) 2012-02-28 US disclosed
EP-2178852-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS Romark Laboratories, L.C. (US) 2010-04-28 EP disclosed
WO-2009035788-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. (US) 2009-03-19 WO disclosed
WO-2009035788-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. (US) 2009-03-19 WO disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122939-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS HAVCR2, EIF2AK2, AADAC RAB9A 1694/4885NPC1 585/4885HSD17B10 921/4885
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS HAVCR2, EIF2AK2, AADAC RAB9A 1694/4885NPC1 585/4885HSD17B10 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.